Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Non-Small Cell Lung Cancer
11 articles
Unmasking the Risk Factors: New Insights into Immune-Mediated Hepatotoxicity in Cancer Immunotherapy
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
Immune Checkpoint Inhibitor Rechallenge: A New Hope for Cancer Patients
Meta-analysis shows ICI rechallenge may be safe and effective for some cancer patients who stopped treatment
Sex and Side Effects: New Study Explores Gender Differences in Cancer Immunotherapy
Meta-analysis investigates sex-based differences in adverse events for cancer patients on immunotherapy
Breakthrough Combo Therapy Outperforms Standard Treatment in Advanced Lung Cancer
New drug combination shows promising results in treating advanced EGFR-mutated lung cancer patients.
Capmatinib Shines in METex14 NSCLC: GEOMETRY mono-1 Trial Unveils Promising Results
Final results from GEOMETRY mono-1 trial show capmatinib's efficacy in METex14 NSCLC, especially first-line.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Early-Stage Lung Cancer
Pembrolizumab plus chemotherapy improves survival in resectable early-stage non-small cell lung cancer.
New Hope in Lung Cancer: Dostarlimab Rivals Pembrolizumab in First-Line Treatment
Phase II trial shows dostarlimab plus chemo matches pembrolizumab efficacy for metastatic NSCLC patients.
FLAURA2 Trial: Osimertinib Plus Chemo Boosts Survival in EGFR-Mutated Lung Cancer
Combining osimertinib with chemotherapy significantly improves progression-free survival in NSCLC patients.
Amivantamab Plus Chemotherapy: A New Frontline Treatment for NSCLC with EGFR Exon 20 Insertions
Study shows amivantamab-chemotherapy combo significantly improves outcomes in NSCLC with EGFR mutations
Durvalumab Boosts Survival in Early-Stage Lung Cancer
Study finds perioperative durvalumab plus chemotherapy improves outcomes in resectable NSCLC
Blood Test Predicts Immunotherapy Response in Lung Cancer Patients
Study shows ctDNA blood test can predict immunotherapy response in advanced lung cancer patients